Drug Trial Radar · NCT03562156
A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
Last checked: Nov 20, 2026Latest source record: Feb 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
438
Actual
Start
Aug 16, 2018
Primary completion
Oct 19, 2020
Study completion Aug 6, 2021
Sponsor
- Lead sponsor
- Mycovia Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast infections, is defined as at least 3 episodes of acute VVC in the past 12 months. Several properties of oteseconazole (VT-1161) suggest that it might be a safer and more effective treatment for RVVC than other oral anti-fungal medicines. This study will evaluate the effectiveness and safety of oteseconazole (VT-1161) for the treatment of RVVC and consists of 2 parts. The first part of the study is a 2-week period for the treatment of the patient's current VVC episode with 3 150mg doses of fluconazole. The 2nd part consists of 12 weeks, when the patient will take either oteseconazole (VT-1161) 150 mg or a placebo (according to a random assignment), and then a 36-week follow-up period. In addition, at participating sites, an amendment to the study allows US patients who complete the initial 48 weeks without experiencing a confirmed RVVC episode to continue in a 48-week observational extension period designed to evaluate the continued effectiveness of oteseconazole (VT-1161). This study is identical to VMT-VT-1161-CL-012 (NCT03561701).
Conditions
- Recurrent Vulvovaginal Candidiasis
Interventions
Oteseconazole (VT-1161)Drug
Oteseconazole (VT-1161) 150mg capsule
PlaceboDrug
matching placebo capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects With 1 or More Culture-Verified Acute VVC Episodes During the Maintenance Phase of the Study in the Intent-to-Treat PopulationTime frame: Maintenance phase (post-randomization through Week 48)
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
31123
Birmingham, Alabama
31108
San Diego, California
31139
Lauderdale Lakes, Florida
31143
Sarasota, Florida
31106
Wellington, Florida
31111
Norcross, Georgia
31146
Covington, Louisiana
31105
Metairie, Louisiana
31107
Metarie, Louisiana
31147
Fall River, Massachusetts
31118
Las Vegas, Nevada
31103
Las Vegas, Nevada
31114
Lawrenceville, New Jersey
31142
Port Jefferson, New York
31127
West Seneca, New York
31132
Greensboro, North Carolina
31116
Morehead City, North Carolina
31144
Raleigh, North Carolina
31145
Winston-Salem, North Carolina
31125
Franklin, Ohio
31134
Philadelphia, Pennsylvania
31120
Bristol, Tennessee
31102
Houston, Texas
31117
Draper, Utah
31113
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.